14th Oct 2015 10:40
LONDON (Alliance News) - Verona Pharma PLC said Wednesday the first patients have been dosed in its phase IIa study of RPL554 in chronic obstructive pulmonary disease.
Up to 30 patients will be enrolled in the study, the primary objective of which is to evaluate RPL554 as an addition to standard reliever medications for the disease. Deadline data from the combination study is expected in the second quarter of 2016.
"We believe RPL554 has the potential to become an important new treatment option for COPD patients. This latest study will evaluate the potential of RPL554 when added to existing therapies. We recently announced encouraging results from our standalone Phase IIa study, which demonstrated that the new commercially scalable, suspension formulation of RPL554 is well tolerated and has allowed us to extend the dose range and the duration of bronchodilation effect that can be produced in COPD patients," said Chief Executive Officer Jan-Anders Karlsson in a statement.
Verona is also evaluating RPL554 in a phase IIa trial in asthma, which will report headline data in the first quarter of next year.
Shares in Verona are up 2.00% at 4.08 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
VRP.L